AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03753308 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood Sampling
Description: 5 x Lithium Heparin Tubes WITHOUT DARK GREEN GEL, 5 ml- v. 4 ml Blood volumes collected as part of the usual care and this research comply with the recommendations of Jarde's law for an observational study (less than 80 ml in one day and less than 160 ml over 30 consecutive days for a subject over 40kg).
Study NCT03753308 — intervention group
Intervention type: BIOLOGICAL
Intervention: Liver biopsy
Description: The liver biopsy is part of the usual care and it follows the usual procedure of CHUGA:~The patient is placed in a supine position and received a transitory sedation, MEOPA gas (Kalinox®). Also, an ultrasound scan is performed. Local disinfection followed by local anesthesia with Xylocaine® are performed. The biopsy is performed with the Hepafix 17 gauge needle. 1 passage is carried out to obtain a biopsy fragment of at least 20 mm for the diagnosis (if the passage is unsuccessful, a second passage can be performed strictly as part of the usual care and not as part of research). If the biopsy is> 20 mm, a fragment of the excess biopsy specimen (10% or 2 mm) will be cut and used for research in groups 1b and 2. This division is performed by the clinician directly on the fresh specimen
Study NCT01105117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT-385781A (Actelion Epoprostenol)
Description: per Prescribing Information
Study NCT01105117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flolan®
Description: per Prescribing Information
Study NCT01058785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lucanix
Description: Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
Study NCT02111889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C] kinase inhibitor PET [15O]water PET and tumor biopsies.
Description: \[11C\] kinase inhibitor PET (i.e. sorafenib and erlotinib in this study, with the aim to investigate others in future studies) and \[15O\]water PET will be performed before and after 2 weeks of treatment. Tumor biopsies will be performed before and after 2 weeks of therapy.
Study NCT01824420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detrusitol 4mg QD and Oxybutynin ER 5mg QD
Description: Study group
Study NCT01824420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detrusitol 4mg QD
Description: Control group
Study NCT04748575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acai smoothie
Description: Smoothie containing 150g acai pulp
Study NCT04748575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo smoothie
Description: Control smoothie matched nutritionally (macronutrients) and sensorially to the acai smoothie.
Study NCT00797017 — intervention group
Intervention type: DRUG
Intervention: fentanyl
Description: Infection, starting with 12mcg/h (flexible dose)
Study NCT00797017 — intervention group
Intervention type: DRUG
Intervention: fentanyl
Description: (CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
Study NCT00797017 — intervention group
Intervention type: DRUG
Intervention: fentanyl
Description: Bone Fracture, starting with 12mcg/h (flexible dose)
Study NCT00797017 — intervention group
Intervention type: DRUG
Intervention: fentanyl
Description: (FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
Study NCT00797017 — intervention group
Intervention type: DRUG
Intervention: fentanyl
Description: Other Deformity, starting with 12mcg/h (flexible dose)
Study NCT00797017 — intervention group
Intervention type: DRUG
Intervention: fentanyl
Description: (LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
Study NCT00797017 — intervention group
Intervention type: DRUG
Intervention: fentanyl
Description: Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
Study NCT04282824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of saliva
Study NCT01486004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.
Study NCT01486004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovysmen
Description: Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
Study NCT02711501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser-assisted surgery.
Description: laser-assisted surgery
Study NCT02627521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VerifyNow assay
Description: Platelet reactivity Units by VerifyNow assay
Study NCT02627521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VerifyNow assay
Description: Platelet reactivity Units by VerifyNow assay
Study NCT02711501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery by blade
Description: conventional surgery
Study NCT02603757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily
Study NCT02603757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily
Study NCT02056717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administration of dexamethasone 10 mg IV 1 h before UAE
Study NCT02056717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Administration of normal saline 2 mL IV 1 h before UAE
Study NCT01630759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
Study NCT02794155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDV Insulin Lispro
Description: HDV Insulin Lispro: \~1% of the Insulin Lispro is bound to HDV (Hepatocyte Directed Vesicle)
Study NCT02794155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin LISPRO
Description: Insulin Lispro: no bound insulin
Study NCT01630759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive usual diabetes/antinatal care. The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
Study NCT00003157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00003157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00003157 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01498237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photoacoustic endoprobe
Description: The PAE assessment will be performed in the operating room following strict sterile technique. PAE is performed immediately prior to the planned surgery. Participants are prepped following standard protocol. Length of the endometrial cavity is determined by a uterine sound. Endocervix is dilated as needed to allow passage of the PAE probe. The PAE probe will be advanced to the uterine fundus. Images will be obtained during withdrawal of the PAE probe from fundus to the os. Recorded images will allow computer assisted image analysis and functional measurements to be performed. Duration and difficulty of the procedure will be recorded. Comments and complications will be specifically noted.
Study NCT01498237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic endoscopy
Description: Photoacoustic endoscopy probe will be inserted into the endometrial canal to the uterine fundus and images will be obtained during the withdrawal of the probe from the fundus to the endocervical os.
Study NCT02967094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)
Study NCT02967094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of water before upper endoscopy
Study NCT03826043 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample analysis
Description: Thrombophilia, blood count and coagulation count
Study NCT00848263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar plate
Description: Treatment with a volar plate (DVR) inserted through a volar incision of 8-10 cm over the distal radius (Henry's approach).
Study NCT00848263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal nail plate
Description: Treatment with a dorsal nail plate (DNP) inserted through a 3-4 cm dorsal incision.
Study NCT00685529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic formoterol
Description: 12 µg of racemic formoterol fumarate BID
Study NCT00685529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: 15 µg of nebulized arformoterol tartrate inhalation solution BID
Study NCT00685529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic formoterol
Description: 24 µg of racemic formoterol fumarate BID
Study NCT03914495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Powdered inulin will be provided in pre-weighed portions for consumption in a 1 week titration to reduce GI side effects with a 21 day intervention at full dose.
Study NCT03914495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powdered maltodextrin will be provided in pre-weighed portions for consumption in a 1 week titration with a 21 day intervention at full dose.
Study NCT01220986 — intervention group
Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: 0, 30, 60, 90 min post inflow-division
Study NCT04404010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality
Description: Participants randomized to the iVR simulator utilizes a head-mounted display producing 3D visuals with haptic controllers for an immersive operating room experience. The module produced consists of the key steps in performing a reverse shoulder arthroplasty using virtual versions of the equipment used in the real procedure. Prior to initiation, participants will be provided with a safety and training demonstration on the use of the VR module by study personnel. Participants will be provided as much time as they require to watch the video, including repetition if desired, which they will be timed for completion.
Study NCT04404010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surgical Technical Instructional Video
Description: Participants will be provided as much time as they require to watch the instructional video, including repetition if desired, which they will be timed for completion.
Study NCT03528889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Extension and Derotation Osteotomy (ExtFDO)
Description: Correction of malrotation of the femoral bone and flexed knee gait by osteotomy, derotation and osteosynthesis
Study NCT03528889 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Extension and Derotation Osteotomy (ExtFDO)
Description: Correction of malrotation of the femoral bone and flexed knee gait by osteotomy, derotation and osteosynthesis
Study NCT04402853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tears swab
Description: rtPCR on tears swabs samples
Study NCT05341635 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Swab sampling
Description: Collection of three nose-pharyngeal and oral swabs
Study NCT01492699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-03140
Description: 50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
Study NCT01074658 — intervention group
Intervention type: DEVICE
Intervention: Medtronic CoreValve System
Description: Transcatheter Aortic Valve Implantation of the Medtronic CoreValve System
Study NCT04207320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: αβ+ T-cell depletion with Miltenyi CliniMACS system
Description: Haploidentical CD34+ megadose hematopoietic stem cell transplant in which cells are purified using the Miltenyi CliniMACS system designed for αβ+ T-cell receptor selection using immunomagnetic beads.
Study NCT01158729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin (Recombinant)
Description: Single dose of antithrombin (recombinant) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: ATIII dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
Study NCT01158729 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo (0.9% NaCl) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: Placebo dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
Study NCT04369755 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: A MRI in PTX mode will be done on healthy subject (approx. 90 min of sequences)
Study NCT03052439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP
Description: After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.
Study NCT04990661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intradialytic massage
Description: intradialytic massage for lower extremity ( the massage included both feet and legs up to and including the knee) applied to the intervention group in three sessions a week and a total of six sessions for two weeks
Study NCT04436874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: transplant infusion of feces from healthy donors into affected subjects
Study NCT02941276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Electrostimulator device
Description: Patients who will receive a fully functioning device
Study NCT02627521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor administration prior to randomization
Study NCT00305604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin phosphate
Description: Once daily (q.d.) administration of sitagliptin 100 mg tablet (or 50 mg based on creatinine clearance). For up to a 24-wk treatment period.
Study NCT00305604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: sitagliptin matching placebo for up to a 24-wk treatment period.
Study NCT05915936 — intervention group
Intervention type: PROCEDURE
Intervention: LVMR
Description: laoparoscopic ventral mesh rectopexy
Study NCT05915936 — intervention group
Intervention type: PROCEDURE
Intervention: PSR
Description: perineal stapler resection
Study NCT02146248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined oral contraceptive
Description: combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
Study NCT02146248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoProvera
Description: injectable hormonal contraceptive
Study NCT01249534 — intervention group
Intervention type: OTHER
Intervention: gastroesophageal cancer surgery
Description: gastroesophageal cancer surgery
Study NCT04093362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 is an oral FGFR inhibitor
Study NCT04093362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin/Gemcitabine
Description: Cisplatin/Gemcitabine is currently 1st line standard of care
Study NCT03617367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daxibotulinumtoxinA for injection
Description: DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
Study NCT01259973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 1 single dose of 2.5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
Study NCT01259973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 single dose of 2.5mL physiological serum masked in 250 mL of peach juice, for 1 day. Oral administration.
Study NCT01259973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: 1 single dose of 5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
Study NCT04092816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAMILY Intervention
Description: The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials.
Study NCT04569916 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
Study NCT04569916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome
Description: radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
Study NCT04569916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
Study NCT04569916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
Study NCT01422590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Single oral administration of sitagliptin 100 mg
Study NCT02941276 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Electrostimulator device
Description: Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)
Study NCT00944112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Restrictive RBC Transfusion
Description: Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70 g/L with a target Hb concentration of 71-90 g/L during the intervention period.
Study NCT00944112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liberal RBC Transfusion
Description: Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90 g/L with a target Hb concentration of 91-110 g/L during intervention.
Study NCT01589861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 + lapatinib
Description: BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity
Study NCT02147249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic treatment
Description: Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
Study NCT01762124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Native Outflow Tract TPV
Description: Transcatheter placement of a pulmonary valve
Study NCT04565509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Communication Message
Description: A messaging strategy will be developed from focus groups that generally describes COVID-19 and the importance of testing.
Study NCT04565509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focused/Targeted Message
Description: A messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the focus groups input.
Study NCT04565509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best Message Alone
Description: The best message will be either the general or focused/targeted message described above.
Study NCT04565509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best Message + Augmented Message or Implementation Strategy
Description: The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
Study NCT00265850 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV
Study NCT00265850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00265850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV